HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare

Executive Summary

Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.

You may also be interested in...



Nestlé Not Interested In Wider Consumer Health Play, Will Stick To VMS And Nutrition

While Nestle has made a success of its push into the dietary supplements market, don't expect to see the company make a move into the wider consumer health space. The company's Health Science unit recorded double-digit growth in 2021, but will remain focused on its core categories.

GSK In 'Countdown Mode' To Consumer Split As Full Year Sales Slip Back

Two months on from GSK’s rejection of a £50bn bid for Consumer Healthcare from Unilever – and with other suitors seemingly yet to materialize – CEO Emma Walmsley is pressing ahead with the plan to spin off the business in mid-2022. GSK will be buoyed by a strong showing by Consumer Healthcare in Q4, even through full year sales were down slightly.

Prestige Consumer Results During COVID Show Success From Shifting Entirely To Health Care

Sales growth for OTC drug brands during latest quarter contribute to Prestige increasing its full-year guidance for FY2022, which ends on 31 March, for revenues growing around 9% to between $1.075bn and $1.08bn.

Related Content

Topics

UsernamePublicRestriction

Register

RS152129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel